Abeona Therapeutics Inc. Stock News

Geode Capital Management LLC reduced its stake in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) by 40.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 657,021 shares of the biopharmaceutical companys stock after selling 452,168 shares during the quarter. Geode []

Zacks Investment Research upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a hold rating to a buy rating in a report issued on Thursday, Zacks.com reports. Zacks Investment Research currently has $1.00 price target on the biopharmaceutical companys stock. According to Zacks, Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products []

Cantor Fitzgerald restated their overweight rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research report report published on Thursday morning, Zacks.com reports. ABEO has been the topic of a number of other research reports. HC Wainwright reiterated a buy rating and set a $5.00 price target on shares of Abeona Therapeutics in a report []

Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reportin

Abeona Therapeutics (ABEO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i

Abeona Therapeutics Inc. (NASDAQ:ABEO) price on Thursday, November 18, fall -9.76% below its previous days close as a downside momentum from buyers pushed the stocks value to $0.77. A look at the stocks price movement, the close in the last trading session was $0.85, moving within a range at $0.7343 and $0.865. The beta value New Outlook On Abeona Therapeutics Inc. Read More »

Abeona Therapeutics (ABEO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i

Abeona Therapeutics Inc (NASDAQ:ABEO) Analysts at SVB Leerink boosted their Q4 2021 earnings per share estimates for Abeona Therapeutics in a research report issued on Monday, November 15th. SVB Leerink analyst M. Foroohar now expects that the biopharmaceutical company will post earnings of ($0.07) per share for the quarter, up from their previous forecast []

NEW YORK and CLEVELAND, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its sponsorship of the second a

NEW YORK and CLEVELAND, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that information about the comp

NEW YORK and CLEVELAND, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that information about the companys ABO-102 pivotal Transpher A study in Sanfilippo syndrome type A (MPS IIIA) will be presented at the 14 th International Congress of Inborn Errors of Metabolism (ICIEM). The meeting will take place virtually and at the Hilton Sydney in Sydney, Australia on November 21-23, 2021.

Catalyst Biosciences, Inc. (CBIO) with the stream of -2.40% also noticed, India Abeona Therapeutics Inc. (ABEO) encountered a rapid change of -1.77% in the last hour of Tuesdays trading session. The post Bright Stock Buzz: Catalyst Biosciences, Inc. (NASDAQ:CBIO), Abeona Therapeutics Inc. (NASDAQ:ABEO) appeared first on Stocks Equity .

Abeona Therapeutics (NASDAQ:ABEO) posted its quarterly earnings data on Sunday. The biopharmaceutical company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16), Fidelity Earnings reports. Abeona Therapeutics stock traded down $0.02 during mid-day trading on Tuesday, hitting $0.89. The stock had a trading volume of 201 shares, compared to its average volume […]

Abeona Therapeutics (NASDAQ:ABEO) released its quarterly earnings results on Sunday. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, hitting the Zacks consensus estimate of ($0.16), Fidelity Earnings reports. Shares of NASDAQ:ABEO opened at $0.91 on Tuesday. The company has a market cap of $92.18 million, a P/E ratio of -1.57 and a []

NEW YORK and CLEVELAND, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., Chie